Functional dyspepsia( FD)
Conditions
Interventions
Control group (healthy residents):no exposure factor
Treatment group (FD group: Subgroup A, Subgroup B, Subgroup C, Subgroup D):no exposure factor
Sponsors
The Third Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Treatment group: (1) those who agree to participate in this clinical trial and sign a written informed consent form; (2) 18 years old< = age< = 70 years old, with the ability to act independently; (3) 1) Symptoms appeared for at least 6 months before diagnosis, and met the diagnostic criteria for functional dyspepsia Rome IV. postprandial discomfort syndrome or epigastric pain syndrome in the past 3 months, Hp positive or negative, mild to moderate or no gastric mucosal atrophy; 2) or no upper gastrointestinal symptoms, Hp negative, no gastric mucosal atrophy; (4) Those who do not have serious mental illness; (5) Those who have no pregnancy plan within 6 months; 2. Control group: no upper gastrointestinal symptoms, Helicobacter pylori (Hp) negative, no gastric mucosal atrophy; Meets treatment group (1), (2), (4) and (5).
Exclusion criteria
Exclusion criteria: 1. Treatment group: (1) Patients with organic lesions such as peptic ulcer, gastroparesis, gastric cancer, bile reflux gastritis, and a history of abdominal surgery. (2) Patients with overlapping syndromes such as gastroesophageal reflux disease and irritable bowel syndrome. (3) Those who have taken antacids, antibiotics, prokinetic drugs and non-steroidal drugs in the 1 month before the study. (4) Those with moderate to severe anxiety and depression, and have taken anti-anxiety and depression drugs within 3 months. (5) Pregnant and lactating. (6) Patients with hyperuricemia. (7) Those with severe heart disease, such as myocardial infarction, unstable angina, cardiac insufficiency, and severe arrhythmia. or blood pressure > 160/95mmHg after drug control. (8) Combined with severe liver and kidney disease, or abnormal liver and kidney function tests (ALT, AST> = 1.5 times the upper limit of normal, Cr > = 1.2 times the upper limit of normal). (9) Fasting blood glucose > 7 .0mmol/L. (10) Combined with severe endocrine, psychiatric, and nervous system organic diseases. (11) Other conditions that the investigator deems inappropriate to participate in this clinical study. (12) Those who have participated in clinical trials of dyspepsia within 1 year before selection or other clinical trials within 3 months before selection. 2. Control group: The exclusion criteria were the same as those of the treatment group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total treatment effective rate;Clinical remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlations between related proteins/molecules of FD, Hp infection, and CAG and clinical phenotypes, as well as the relationships between diseases and molecular biology.; | — |
Countries
China
Contacts
Public ContactZeng Lifang
The Third Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed